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Abstract
Background: Natural history of paroxysmal atrial fibrillation (AF) is not very well documented.
Clinical experience suggests that paroxysmal AF could progress to chronic AF with estimates
ranging between 15 and 30% over a period of 1–3 years. We performed an epidemiologic study to
elucidate the natural history of paroxysmal AF, this study estimated its incidence in a general
practice setting, identified associated factors and analyzed the progression into chronic AF as well
as the mortality rate.
Methods: Using the UK General Practice Research Database (GPRD), we identified patients aged
40–89 years with a first-recorded episode of paroxysmal AF during 1996. Risk factors were
assessed using 525 incident paroxysmal AF cases confirmed by the general practitioner (GP) and a
random sample of controls. We follow-up paroxysmal AF patients and estimated their mortality
rate and progression to chronic AF.
Results: The incidence of paroxysmal AF was 1.0 per 1,000 person-years. Major risk factors for
paroxysmal AF were age and prior valvular heart disease, ischaemic heart disease, heart failure and
hyperthyroidism. During a mean follow-up of 2.7 years, 70 of 418 paroxysmal AF patients with
complete information progressed to chronic AF. Risk factors associated with progression were
valvular heart disease (OR 2.7, 95% CI 1.2–6.0) and moderate to high alcohol consumption (OR
3.0, 95% CI 1.1–8.0). Paroxysmal AF patients did not carry an increased risk of mortality, compared
to an age and sex matched sample of the general population. There was a suggestion of a small
increased risk among patients progressing to chronic AF (RR 1.5, 96% CI 0.8–2.9).
Conclusion: Paroxysmal AF is a common arrhythmia in the general practice setting, increasing
with age and commonly associated with other heart diseases. It sometimes is the initial
presentation and then progress to chronic AF. A history of valvular heart disease and alcohol
consumption are associated with this progression.
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Background
The incidence and natural history of paroxysmal atrial
fibrillation (AF) have not been well studied[1]. Paroxys-
mal AF is usually defined temporally as intermittent peri-
ods of AF intertwined with episodes of normal sinus
rhythm, normally lasting less than a week [2,3]. It could
be a unique self-terminating episode of AF or recurrent
ones [4]. When the arrhythmia is sustained in time, AF is
designated persistent or chronic AF. However, the differ-
entiation of paroxysmal AF from more chronic forms of
AF is often based on the history given by symptomatic
patients. This could be misleading, as asymptomatic par-
oxysmal AF is quite common [5,6]. Paroxysmal AF may be
the initial presentation of the arrhythmia or can continue
with recurrent episodes that may eventually become
chronic as the end result AF[4,7,8]. Some reports have
shown that about 25% of paroxysmal AF patients will
develop a more persistent form of AF [3]. The rate of tran-
sition from paroxysmal to chronic varies considerably
with the underlying aetiology, being more frequent
among patients with rheumatic heart disease and ischae-
mic heart disease. Progression from paroxysmal to
chronic form does not depend on age or gender but on
longer duration of the initial paroxysmal AF episode [8,9].
Most of the studies published on atrial fibrillation
patients are based on hospital patients, or cohorts of
patients undergoing specific clinical diagnostic tests and
procedures. We performed an epidemiologic study in the
general practice setting using information recorded by the
general practitioners during their daily consultations.
The objectives of this study were to estimate the incidence
rate of paroxysmal AF as compared with chronic AF in a
general practice setting [10], to describe comorbidity and
health care utilization and to identify factors associated
with paroxysmal occurrence. We also estimated the rate of
progression to chronic AF, as well as the mortality rate
among patients with first-detected paroxysmal AF.
Methods
We performed a cohort study using data from the General
Practice Research Database (GPRD). The general practi-
tioners (GPs) who anonymously provide the GPRD with
their data systematically record information on demo-
graphics, medical diagnoses, referrals to consultants and
hospitals, and written prescriptions for their patients. The
database contains computerized information for more
than two million residents in the UK registered with GPs
and is administered by the Medicines and Healthcare
products Regulatory Agency (MHRA), which organizes
this information to be used for research projects. Numer-
ous epidemiological studies support its validity and data
completeness, including a recent study on AF [11,12].
Study population
We identified a total of 703,777 patients in the GPRD
meeting the following conditions during 1996. Patients
were 40–89 years old, enrolled with a GP for more than 2
years and with at least one health contact before January
1996. These eligibility criteria were applied to ensure that
all study members had incurrred in some recent contact
with the GP prior to entering the study period and were
then at risk of being cared "actively" by their GP. Patients
with a code for heart rhythm disorders (ICD 8th edition:
4160–4169) or cancer (ICD 8th: 1400–2099) before Jan-
uary 1996 were omitted.
Case definition and validation
We identified 2,098 patients attending to the general prac-
titioner with a first-ever recorded diagnosis of AF/flutter
(ICD 8th: 4163). After reviewing the computerized
records for all of them, 1,972 patients were considered
potential cases of AF. For all of them a questionnaire was
sent to the GPs requesting additional information. Addi-
tionally, 623 patients with unspecific codes of supra-ven-
tricular and sinus arrhythmias other than AF were
identified. Since these codes could mask a diagnosis of AF,
we sent a questionnaire to an approximately 10% random
sample (n = 68). The GP was asked to confirm the diagno-
sis of AF, and to classify it as chronic or paroxysmal based
on the following criteria: Chronic AF was defined as per-
sistence of the arrhythmia, with the episode of AF not con-
verting to sinus rhythm within 1 week (this definition
include persistent and permanent AF cases on terminol-
ogy proposed by the ACC/AHA/ESC guidelines) [4]. We
considered paroxysmal AF when the arrhythmia did revert
spontaneously or following treatment to sinus rhythm
within a week. We also requested the GPs to confirm
whether this diagnosis was the first ever and to provide
information on diagnostic tests, procedures and aetiology
of the AF. Patient confidentiality was always preserved.
We received 1,888 valid questionnaires (95% response
rate). Five hundred twenty-five patients were confirmed as
paroxysmal AF cases and 1,109 were patients with chronic
AF. The remaining patients were not confirmed as having
AF (n = 125) or had an episode of AF before entering the
study period (n = 129). The confirmation rate was 98%
among patients originally identified with AF codes and
30% among those with unspecific codes of arrhythmia.
Patients with chronic forms of AF were analysed sepa-
rately, and the main results have been published recently
[10,12].
Incidence analysis
We estimated the incidence rate of paroxysmal AF strati-
fied by age groups and sex. We used confirmed incident
cases of paroxysmal AF as the numerator and the sum ofBMC Cardiovascular Disorders 2005, 5:20 http://www.biomedcentral.com/1471-2261/5/20
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person-years in the study population as the denominator
within age and sex strata.
Nested case-control analysis to ascertain risk factor for 
paroxysmal AF
We used all confirmed cases of paroxysmal AF (as in the
cohort analysis), and their index date was the date of the
paroxysmal AF diagnosis. We then assigned a random
date between 1 January and 31 December 1996 to all
members of the study population. If this random date was
included in her/his contribution of person-time to the
study, that person became an eligible control and we used
that date as index date. Finally, 5,000 controls were ran-
domly sampled from the pool of eligible controls. This
selection process warrants that the likelihood of being
selected as a control is proportional to the person-time at
risk.
We used the information recorded by the GP in the com-
puterized database for both cases and controls to ascertain
demographic data, as well as the prevalence of medical
history before index date for the following conditions:
ischaemic heart disease (IHD), valvular disease, heart fail-
ure (HF), hypertension, cerebrovascular disease (CVD),
diabetes and hyperthyroidism. We also ascertained the
role of smoking status, body mass index (BMI) and alco-
hol consumption. We computed estimates of the odds
ratio (OR) and 95% confidence interval (CI) of AF associ-
ated with risk factors, using unconditional logistic regres-
sion adjusted by age and sex.
Mortality follow-up analysis
Using the study population in which AF patients were
identified and applying the same eligibility criteria as for
the AF cohort, we randomly sampled a cohort of 5,000
individuals free of AF, matched to the cohort of paroxys-
mal AF patients by age and sex. The paroxysmal AF cohort
was followed up from date of AF diagnosis and the general
population cohort from a random date during 1996 until
the earlier of either death or end of follow-up (April
2001). Survival probability was computed in both
cohorts, and we estimated the relative risk (RR) of mortal-
ity associated with AF, using Cox proportional hazard
regression. We retrieved death information from compu-
terized files and from the questionnaire filled by the GP,
and ascertained the cause of death using the two sources
of information.
Follow-up analysis for progression to chronic AF
In order to assess which paroxysmal AF patients pro-
gressed to chronic AF, we sent a second questionnaire to
the GPs requesting depersonalised copies of medical
records for all paroxysmal AF patients. At the time of this
second request, we received valid information on 418
cases; the remaining patients (n = 107) were no longer
reachable. The GPs confirmed that 70 patients (17%)
developed chonic AF before April 2001, 192 continued
with recurrent episodes of paroxysmal AF and the remain-
ing (n = 156) did not present any more episodes after the
first one.
We used a life table analysis to show the proportion of
patients with initial paroxysmal AF, that progressed to
chronic AF during the follow-up period.
A nested case-control analysis was performed among the
418 paroxysmal AF patients with valid information to
assess risk factors for progression to chronic forms. In this
analysis, we used as cases the 70 patients who progressed
to chronic AF, and we used their date of diagnosis of
chronic AF as index date. All remaining AF patients (n =
348) were used as controls. Estimates of progression risk
and 95% CI were computed using unconditional logistic
regression. We collected recorded information on the fol-
lowing risk factors: smoking status, BMI and alcohol con-
sumption, as well as prior history of HF, valvular disease,
IHD, CVD, hypertension and diabetes. We assessed the
association between drug treatment and the development
of persistent AF. We also estimated the mortality rate in
both groups: those who had paroxysmal AF and those
who developed chronic AF.
Results
The incidence rate of paroxysmal AF was 1.0 per 1000 per-
son-years (95% CI 0.9–1.1). In a previous reported study
on the same source population we found that the inci-
dence of chronic AFwas higher (1.7, 95% CI 1.6–1.8)
[10]. The incidence increased with age in both AF groups,
but this was more pronounced among persons aged 70
years and older in the cohort of chronic AF, compared
with the paroxysmal AF cohort (Fig. 1). The incidence of
paroxysmal AF was similar in males and females.
Characteristics of the 525 patients with incident paroxys-
mal AF are shown in Table 1. The mean age at presenta-
tion was significantly higher in the female population (73
years; SD = 10) than in the male population (67 years; SD
= 11). The most frequent aetiology among initially
detected paroxysmal AF as assigned by the GP was IHD in
both sexes (43%), while no specific cause was given in
32% of the cases. Less than a third of patients with an ini-
tial paroxysmal AF episode had a cardioversion attempt
close to the time of diagnosis. Digoxin and beta-blockers
were the most frequently prescribed drugs during the 3
months after the paroxysmal AF episode. Close to half of
the paroxysmal AF patients (48%) did not receive warfa-
rin or aspirin during the first 3 months after diagnosis.
Baseline characteristics of paroxysmal AF patients and
controls are shown in Table 2. Age was the mostBMC Cardiovascular Disorders 2005, 5:20 http://www.biomedcentral.com/1471-2261/5/20
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important risk factor for paroxysmal AF. Individuals 70
years old or more presented a relative risk greater than
eight-fold of developing paroxysmal AF after adjustment
for cardiovascular comorbidity and other risk factors.
Male patients and those with a moderate to high alcohol
consumption carried an increased risk of paroxysmal AF.
Close to 70% of paroxysmal AF patients presented some
cardiovascular morbidity compared with 29% of controls.
Hypertension and IHD were the most prevalent diagnoses
in both groups (Table 2). Patients with underlying valvu-
lopathies had a four-fold increased risk of having paroxys-
mal AF. Other conditions independently associated with
the development of paroxysmal AF were heart failure (OR
2.5; 95% CI 1.8–3.5) and hyperthyroidism (OR 3.6; 95%
CI 2.0–6.5). We did not find any major association with
diabetes.
During a mean follow-up period of 2.7 years, 67 paroxys-
mal AF patients died. The mortality rate among paroxys-
mal AF patients was 4.2 per 100 person-years. The relative
risk of mortality among paroxysmal AF patients was simi-
lar to that in an age and sex matched sample of the general
population free of AF after adjustement for other co-
comorbidity (table 3). The most frequent cause of death
was heart disease including IHD (46.3%), followed by
cancer (13.4%). In nine cases, no specific cause of death
was assigned.
Seventy patients with paroxysmal AF eventually pro-
gressed into chronic AF during the follow-up period. The
progression rate was 6.2 per 100 person-years, with a
slightly higher rate among men (6.8 per 100 person-years)
than women (5.6 per 100 person-years). Fig. 2 shows the
proportion of patients developing chronic AF over time,
using life table analysis. It also present the number of
patients with paroxysmal AF at risk and the number of
patients progressing to chronic AF in each time interval.
Patients dying or leaving the practice were censored from
follow-up. More than half of the cases of progression (n =
48) occurred during the first year after the initially parox-
ysmal AF onset, resulting in a progression rate of 13.6 per
Incidence of paroxysmal atrial fibrillation in comparison to chronic atrial fibrillation in UK General Practice [10] Figure 1
Incidence of paroxysmal atrial fibrillation in comparison to chronic atrial fibrillation in UK General Practice [10].BMC Cardiovascular Disorders 2005, 5:20 http://www.biomedcentral.com/1471-2261/5/20
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100 person-years during the first year of follow-up.
Among those not progressing to chronic AF (n = 348), 156
had only the initial single episode recorded and 192 pre-
sented recurrent episodes of paroxysmal AF during follow-
up.
Figure 3 presents the main characteristics studied as
potential risk factors for the progression to chronic AF.
Age and sex were not associated with progression to per-
sistent AF. Only cardiac morbidity, mainly valvular dis-
ease and heart failure were associated with significantly
greater risk of developing chronic AF. Moderate to high
consumption of alcohol (more than 21 units per week)
was associated with a three-fold increased risk of progres-
sion (fig. 3). We did not find any association between use
of antiarrhytmic drugs after initial diagnosis of paroxys-
mal AF and progression or not to chronic forms of AF
(data not shown), but we observed that patients progress-
ing to persistent AF were more likely to have been treated
with warfarin after their initial PAF diagnosis (OR: 2.9;
95%CI: 1.6–1.9) compared to those not progressing.
Eleven patients died among the patients progressing to
chronic AF and 39 in the subgroup not progressing. The
mortality rate was higher among patients progressing to
chronic AF (5.2 per 100 person-years) than in the group
who did not (3.6 per 100 person-years). The age- and sex-
adjusted relative risk of mortality was 1.5 (95% CI 0.8–
2.9) among patients who had progressed to sustained
forms of AF, compared with those not progressing.
Discussion
This is the first study, to our knowledge presenting follow-
up data in patients initially diagnosed with paroxysmal
Table 1: Distribution of age, aetiology, diagnostic tests and pattern of treatment among paroxysmal atrial fibrillation patients by sex
Female Male
n = 268 (%) n = 257 (%)
Age
40–59 30 (11.2) 63 (24.5)
60–69 57 (21.3) 74 (28.8)
70–79 107 (39.9) 81 (31.5)
80+ 74 (27.6) 39 (15.2)
AF aetiology assigned by the GP*
IHD 117 (43.7) 110 (42.8)
Valvular 24 (9.0) 13 (5.1)
Other cardiac diseases 19 (7.1) 20 (7.8)
Non-cardiac diseases 28 (10.4) 16 (10.1)
Unknown 80 (29.9) 88 (34.2)
Tests done to confirm diagnosis
ECG alone 158 (59.0) 170 (66.1)
Other test (with/
without ECG)
46 (17.1) 33 (12.8)
Unknown 64 (23.9) 54 (21.0)
Cardioversion attempts
No or unknown 178 (66.4) 170 (66.2)
Pharmacological only 79 (29.5) 69 (26.8)
Electrical only 8 (3.0) 13 (5.1)
Both 3 (1.1) 5 (1.9)
Use of AF treatment drugs †
Amiodarone 27 (10.1) 40 (15.6)
Verapamil 8 (3.0) 7 (2.7)
Diltiazem 13 (4.9) 13 (5.1)
Beta-blockers 82 (30.6) 65 (25.3)
Digoxin 100 (37.3) 80 (31.1)
Use of antithrombotics/anticoagulants†
No use 136 (50.7) 115 (44.7)
Warfarin only 28 (10.4) 36 (14.0)
Aspirin only 92 (34.3) 91 (35.4)
Both 12 (4.5) 15 (5.8)
*17 cases (3.2%) had the episode after a cardiovascular surgery.
†In the first 3 months after initial diagnosis.BMC Cardiovascular Disorders 2005, 5:20 http://www.biomedcentral.com/1471-2261/5/20
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atrial fibrillation from the perspective of a general practice
setting, and we found the annual incidence of paroxysmal
AF to be 1.0 per 1000 person-years. A slightly lower inci-
dence rate (0.6 per 1000) has been reported in a study
where paroxysmal AF patients attending hospital were
identified [13]. The incidence of paroxysmal AF was
almost half the one we reported for chronic AF in the
same source population [10]. This is well in line with
Table 2: Risk of paroxysmal atrial fibrillation associated with age, sex, and other factors
Paroxysmal AF cases Controls
n = 525 (%) n = 5000 (%) OR* (95% CI)
Age
40–49 31 (5.9) 1565 (31.3) 1
50–59 62 (11.8) 1343 (26.9) 2.1 (1.3–3.2)
60–69 131 (25.0) 997 (19.9) 5.0 (3.3–7.5)
70–79 188 (35.8) 769 (15.4) 8.3 (5.5–12.5)
80–89 113 (21.5) 326 (6.5) 10.9 (7–17.1)
Sex
Female 268 (51.0) 2647 (52.9) 1
Male 257 (49.0) 2353 (47.1) 1.3 (1.0–1.6)
Smoking†
Non-smoker 313 (59.6) 2736 (54.7) 1
Smoker 94 (17.9) 1226 (24.5) 0.8 (0.6–1.0)
Ex-smoker 42 (8.0) 280 (5.6) 1.0 (0.7–1.5)
Body mass index (BMI) †
<20 25 (4.8) 201 (4.0) 1.4 (0.9–2.4)
20–24 135 (25.7) 1466 (29.3) 1
25–29 162 (30.9) 1420 (28.4) 1.1 (0.8–1.4)
30+ 62 (11.8) 601 (12.0) 1.1 (0.8–1.5)
Alcohol consumption (units per week) †#
None 185 (35.2) 1597 (31.9) 1
1–7 units 114 (21.7) 1112 (22.2) 1.2 (0.9–1.6)
8–21 units 69 (13.1) 718 (14.4) 1.4 (1.0–1.9)
>21 units 31 (5.9) 292 (5.8) 1.7 (1.1–2.6)
Comorbidity
IHD 156 (29.7) 415 (8.3) 2.1 (1.6–2.6)
Valvular disease 30 (5.7) 41 (0.8) 4.2 (2.4–7.3)
Heart failure 81 (15.4) 117 (2.3) 2.5 (1.8–3.5)
Hypertension 197 (37.5) 859 (17.2) 1.4 (1.2–1.8)
Cerebrovascular 
disease
68 (13.0) 195 (3.9) 1.5 (1.1–2.1)
Diabetes 36 (6.9) 194 (3.9) 0.9 (0.6–1.4)
Hyperthyroidism 19 (3.6) 44 (0.9) 3.6 (2.0–6.5)
*OR: Odds ratio adjusted by age, sex and all the variables in the table, using unconditional logistic regression.
†Missing data in smoking (15.1%), BMI (26.3%) and alcohol use (25.5%).
# 1 unit = 10 mL of pure ethanol.
Table 3: Mortality rate and relative risk of death associated with paroxysmal atrial fibrillation
Age and sex matched Cohort free of AF n = 5000 Paroxysmal AF cohort n = 525
Person-years 14298 1606
Deaths 483 67
Mortality rate/100 person-years (95% CI) 3.38 (3.09–3.69) 4.17 (3.30–5.26)
Relative risk (95% CI) 1 1.2 (1.0–1.6)
Adjusted relative risk*(95% CI) 1 1.0 (0.75–1.3)
*Relative risk estimated by Cox regression model, including age, sex, smoking, heart failure, ischaemic heart disease, hypertension, cerebrovascular 
disease and diabetes.BMC Cardiovascular Disorders 2005, 5:20 http://www.biomedcentral.com/1471-2261/5/20
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what has been reported previously – that paroxysmal epi-
sodes represent between 35% and 66% of all cases of AF,
depending on the study population and the definitions
used [1,3,14]. It has been reported that the load of
patients with atrial fibrillation is likely to increase sub-
stantially in the next years, explained only in part by the
aging of the population [15]. Our results show, as previ-
ously reported, that patients with paroxysmal AF are
younger and have less comorbidity than patients with
chronic AF [10,13,16]. This age difference could reflect the
progressive nature of AF. The differences in morbidity and
mortality among the two forms of AF suggest the possibil-
ity that paroxysmal and persistent AF may be different dis-
eases with different risk factors and different pathogenic
substrates, although clearly overlapping in part [17-19],
paroxysmal being a more benign disease than chronic.
It is difficult to assess an underlying cause in all AF
patients [3]. In our study, the specific cause was not
reported in 32% of paroxysmal AF patients. We observed
that the most frequent underlying associated conditions
in paroxysmal AF were coronary heart disease, rheumatic
heart disease and hypertension. These causes have also
been found for chronic AF [12], although there appears to
be a great variability between studies.
It has been recommended that pharmacological manage-
ment of patients with newly discovered AF requires
knowledge of its pattern of presentation (paroxysmal, per-
sistent, or permanent) [4]. Anticoagulation with warfarin
has been proposed for patients with paroxysmal forms
when there is underlying heart disease [9,20-22], as no
major differences in risk of stroke between chronic and
paroxysmal AF have been reported. However it is not clear
whether patients with limited episodes of paroxysmal AF
require anticoagulation, and the decision must be
individualized for each patient [4]. We found that close to
half of the patients attending general practice with initial
Proportion of patients with paroxysmal atrial fibrillation progressing to chronic AF Figure 2
Proportion of patients with paroxysmal atrial fibrillation progressing to chronic AF. Number of patients at risk and number of 
new chronic AF cases in each time period, in UK General Practice.BMC Cardiovascular Disorders 2005, 5:20 http://www.biomedcentral.com/1471-2261/5/20
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Risk of progression to chronic atrial fibrillation among paroxysmal atrial fibrillation patients (Odds ratio estimates adjusted by  age and sex, using logistic regression) Figure 3
Risk of progression to chronic atrial fibrillation among paroxysmal atrial fibrillation patients (Odds ratio estimates adjusted by 
age and sex, using logistic regression).BMC Cardiovascular Disorders 2005, 5:20 http://www.biomedcentral.com/1471-2261/5/20
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paroxysmal AF were not given warfarin or aspirin in the
three months after the first-detected episode – a higher
proportion than the one we observed among patients
with chronic forms of AF [10]. This could be due in part
to the fact that 37% of patients with paroxysmal AF pre-
sented a single episode of paroxysmal AF without any
recurrence during the follow-up, and consequently anti-
coagulant or antiplatelet therapies may not be recom-
mended in this subgroup of patients [19].
Clinical experience suggests that paroxysmal AF is often
perpetuated and frequently it progresses to chronic AF,
with estimates ranging between 20% and 30% within a
period of 1–3 years [1,23,24]. A ten year follow-up study
of paroxysmal patients in Trieste reported that 34% devel-
oped chronic AF [18]. The rate of progression varied
according to aetiology, with patients with rheumatic valve
disease carrying the highest rate of progression (66%) [4].
A recent 14 years follow up study on Japanese patients
with initial paroxysmal AF, reported that 77% of them
developed into its chronic form (5,5% of patients per
year) [25]. In our study, we found that 17% of paroxysmal
AF patients progressed to chronic AF during an average
follow-up of close to 3 years, and history of valvular heart
disease and moderate to high alcohol consumption were
identified as the major independent predictors of progres-
sion to chronic AF.
Only a few small studies have examined factors predicting
progression from paroxysmal to persistent AF [23,24]. The
study by Abe et al. of 122 consecutive patients with parox-
ysmal AF reported a progression of 11% to chronic AF
during a period of 2 years. They did not find any signifi-
cant differences in age, sex or presence of organic heart
diseases in the patients who developed chronic AF, com-
pared with paroxysmal AF patients who did not
progress[23]. Another study reported an annual
progression rate of 22% [24]. Chronic and persistent
forms of AF have been reported to carry a greater mortality
than paroxysmal AF [17,23,24]. Our study suggests that
patients progressing to chronic AF had a slightly higher
increased risk of mortality than those not progressing.
Some limitations need to be taken into account when
interpreting our results. Our findings are the reflection of
detection and management of patients with newly diag-
nosed AF in general practice. Furthermore, our data are
based on physicians assessments of patients symptoms
and when available results from diagnostic tests to deter-
mine if the atrial fibrillation was paroxysmal or chronic
(we could not specifically distinguish between permanent
or persistent), and consequently will not be as accurate as
prospective studies based on events detected after Holter
monitoring, pacemaker insertion or ablation surgery. Our
study was observational based on the information
recorded by general practitioners during their daily prac-
tice. This shares the limitations of insufficient information
at times but has the advantage to study the occurrence and
determinants of AF patients in the real world of general
practice. Therefore, it is likely that we may not have ascer-
tained all cases of paroxysmal atrial fibrillation occurring
in the study population, resulting in some underestima-
tion of paroxymal AF. We found that a large proportion of
patients had a unique episode of PAF, but we could not
verify whether this was due to effective treatment with
antiarrhythmic drugs or was incomplete reporting of sub-
sequent paroxysmal episodes.
As we rely on the judgment of the GPs as well as their
records and tests, some information was missing, for
example GP could not assign a specific aetiology in 32%
of paroxysmal AF patients, and we could not distinguish
between those who would truly be "lone AF" and those
with an underlying etiology not recorded by the GP. Also
the rate of progression from paroxysmal to chronic AF
could have been underestimated as we did not obtain
complete response for all followed-up patients.
Conclusion
In summary, we observed that paroxysmal AF is a com-
mon arrhythmia in a general practice setting, increases
with age, and is commonly associated with other cardiac
morbidity. Paroxysmal AF is sometimes the initial presen-
tation of an arrhythmia progressing to chronic AF. Valvu-
lar heart disease and alcohol consumption are associated
with this progression. Patients with paroxysmal AF do not
present an increased risk of mortality compared to the
general population after adjustment for other comorbid-
ity, except among the subgroup progressing to chronic AF
where a small mortality excess risk was observed.
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